|Mr. Xiang Miao||Pres & Non-Independent Director||N/A||N/A||1973|
|Mr. Haifa Zheng||Vice Chairman & VP||N/A||N/A||1964|
|Ms. Hui Zhou||Chief Financial Officer||N/A||N/A||1972|
|Mr. Jiankai Liu||VP & Non-Independent Director||N/A||N/A||1970|
|Ms. Jin Tao||Board Sec.||N/A||N/A||1983|
Shenzhen Kangtai Biological Products Co., Ltd. researches, develops, produces, and sells various types of human vaccines in China. The company's products include cell-free whitebait b-type haemophilus influenzae combined vaccine, SARS-COV-2 vaccine, recombinant hepatitis B vaccine, 23-valent pneumococcal polysaccharide vaccine, diphtheria tetanus acellular pertussis and haemophilus influenzae type b combined vaccine, haemophilus influenzae type b conjugate vaccine, measles and rubella combined with live attenuated vaccine, 13-valent pneumococcal conjugate vaccine, rabies vaccine, inactivated poliomyelitis vaccine, and HIB conjugate vaccine. It has an agreement between YTB and Yong Tai Berhad in relation to the development and commercialization of Covid-19 inactivated vaccine in Malaysia. Shenzhen Kangtai Biological Products Co., Ltd. was founded in 1992 and is based in Shenzhen, China.
Shenzhen Kangtai Biological Products Co., Ltd.’s ISS Governance QualityScore as of September 1, 2023 is 8. The pillar scores are Audit: 4; Board: 9; Shareholder Rights: 5; Compensation: 7.